WO2026082164A1 - Complexe récepteur de lymphocytes t à double ciblage modifié et son utilisation pharmaceutique - Google Patents

Complexe récepteur de lymphocytes t à double ciblage modifié et son utilisation pharmaceutique

Info

Publication number
WO2026082164A1
WO2026082164A1 PCT/CN2025/128398 CN2025128398W WO2026082164A1 WO 2026082164 A1 WO2026082164 A1 WO 2026082164A1 CN 2025128398 W CN2025128398 W CN 2025128398W WO 2026082164 A1 WO2026082164 A1 WO 2026082164A1
Authority
WO
WIPO (PCT)
Prior art keywords
tcr
targeting
dual
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/128398
Other languages
English (en)
Inventor
Tao Jin
Ke Zhang
Pin Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scg Cell Therapy Pte Ltd
Original Assignee
Scg Cell Therapy Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scg Cell Therapy Pte Ltd filed Critical Scg Cell Therapy Pte Ltd
Publication of WO2026082164A1 publication Critical patent/WO2026082164A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4265—Alpha-feto protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente demande concerne un complexe récepteur de lymphocytes T à double ciblage modifié et des cellules immunitaires ainsi modifiées. L'invention concerne également les molécules d'acide nucléique codant pour le complexe récepteur de lymphocytes T à double ciblage modifié, les vecteurs comprenant les molécules d'acide nucléique, les cellules hôtes ou les cellules immunitaires comprenant les vecteurs, les procédés de préparation des cellules immunitaires, les compositions pharmaceutiques comprenant le complexe récepteur de lymphocytes T à double ciblage modifié, des molécules d'acide nucléique, des vecteurs, des cellules hôtes ou des cellules immunitaires, ainsi que l'utilisation du complexe récepteur de lymphocytes T à double ciblage modifié, des molécules d'acide nucléique, des vecteurs, des cellules hôtes, des cellules immunitaires et/ou des compositions pharmaceutiques dans la préparation de médicaments pour la prévention et/ou le traitement et/ou le traitement d'appoint du cancer, le retardement de la progression du cancer, et la réduction et/ou l'inhibition de la récurrence tumorale.
PCT/CN2025/128398 2024-10-18 2025-10-17 Complexe récepteur de lymphocytes t à double ciblage modifié et son utilisation pharmaceutique Pending WO2026082164A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202411463660.3 2024-10-18
CN202411463660 2024-10-18

Publications (1)

Publication Number Publication Date
WO2026082164A1 true WO2026082164A1 (fr) 2026-04-23

Family

ID=97598876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2025/128398 Pending WO2026082164A1 (fr) 2024-10-18 2025-10-17 Complexe récepteur de lymphocytes t à double ciblage modifié et son utilisation pharmaceutique

Country Status (1)

Country Link
WO (1) WO2026082164A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084018A1 (fr) * 2017-10-23 2019-05-02 City Of Hope Car pour le traitement d'une infection par le vih
WO2019242632A1 (fr) * 2018-06-19 2019-12-26 1§1Nanjing Legend Biotech Co., Ltd. Cellules modifiées et utilisations associées
WO2021067347A1 (fr) * 2019-09-30 2021-04-08 Bluebird Bio, Inc. Complexes d'immunorécepteurs régulés par un agent de dimérisation
WO2022007784A1 (fr) * 2020-07-06 2022-01-13 Nanjing Legend Biotech Co., Ltd. Méthodes de réduction du rejet de greffe dans une thérapie cellulaire allogénique
WO2023288267A1 (fr) * 2021-07-14 2023-01-19 2Seventy Bio, Inc. Récepteurs de lymphocytes t modifiés fusionnés à des domaines de liaison d'anticorps

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084018A1 (fr) * 2017-10-23 2019-05-02 City Of Hope Car pour le traitement d'une infection par le vih
WO2019242632A1 (fr) * 2018-06-19 2019-12-26 1§1Nanjing Legend Biotech Co., Ltd. Cellules modifiées et utilisations associées
WO2021067347A1 (fr) * 2019-09-30 2021-04-08 Bluebird Bio, Inc. Complexes d'immunorécepteurs régulés par un agent de dimérisation
WO2022007784A1 (fr) * 2020-07-06 2022-01-13 Nanjing Legend Biotech Co., Ltd. Méthodes de réduction du rejet de greffe dans une thérapie cellulaire allogénique
WO2023288267A1 (fr) * 2021-07-14 2023-01-19 2Seventy Bio, Inc. Récepteurs de lymphocytes t modifiés fusionnés à des domaines de liaison d'anticorps

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARABALLO GALVA LEIDY D ET AL: "Engineering T cells for immunotherapy of primary human hepatocellular carcinoma", JOURNAL OF GENETICS AND GENOMICS, ELSEVIER LTD, AMSTERDAM, NL, vol. 47, no. 1, 20 January 2020 (2020-01-20), pages 1 - 15, XP086099879, ISSN: 1673-8527, [retrieved on 20200128], DOI: 10.1016/J.JGG.2020.01.002 *
MINAEI NEDA ET AL: "Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future", EUROPEAN JOURNAL OF CELL BIOLOGY, WISSENSCHAFLICHE VERLAGSGESELLSCHAFT, STUTTGART, DE, vol. 102, no. 1, 17 December 2022 (2022-12-17), XP087253243, ISSN: 0171-9335, [retrieved on 20221217], DOI: 10.1016/J.EJCB.2022.151284 *
TAN ANTHONY T ET AL: "Adoptive T-cell therapy for HBV-associated HCC and HBV infection", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 176, 19 February 2020 (2020-02-19), XP086088063, ISSN: 0166-3542, [retrieved on 20200219], DOI: 10.1016/J.ANTIVIRAL.2020.104748 *

Similar Documents

Publication Publication Date Title
TWI771677B (zh) 靶向ｂｃｍａ的工程化免疫細胞及其用途
JP7555625B2 (ja) 治療用化合物及び方法
TWI771678B (zh) 靶向ｂｃｍａ的工程化免疫細胞及其用途
AU2017366739B2 (en) Synthetic immune receptors and methods of use thereof
US11299525B2 (en) Chimeric antigen receptor-modified immune effector cell carrying PD-L1 blocking agent
JP7717686B2 (ja) キメラｃｄ３融合タンパク質と抗ｃｄ３ベースの二重特異性ｔ細胞活性化エレメントの複合発現
CN116940670B (zh) 一种新型嵌合受体组合物、重组载体、细胞及其应用
WO2022199125A1 (fr) Cellule immunitaire pour la sécrétion autocrine de protéine de fusion il-15 et anti-pd1
CN107936120B (zh) Cd19靶向性的嵌合抗原受体及其制法和应用
WO2020151752A1 (fr) Cellules immunitaires modifiées ciblant une combinaison cd20
CN109897114A (zh) 具有自杀基因开关的靶向cd47的工程化免疫细胞
JP7764035B2 (ja) 細胞治療の方法
WO2026082164A1 (fr) Complexe récepteur de lymphocytes t à double ciblage modifié et son utilisation pharmaceutique
HK40110123A (zh) 靶向bcma的工程化免疫细胞及其用途
CN114540311A (zh) 一种免疫细胞及其应用
HK40062446B (zh) 靶向bcma的工程化免疫细胞及其用途
Mukantayev et al. ROLE OF MONOCLONAL ANTIBODIES AGAINST THE PROGRAMMABLE DEATH (PD-1) RECEPTOR OF T-CELLS IN TARGETED THERAPY OF MELANOMA